Idelalisib was the first PI3K inhibitor to be approved by the United States Food and Drug Administration (FDA) for chronic lymphocytic leukemia (CCL), follicular lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).3 Here, PIK3CA is linked to B-cell chronic lymphocytic leukemia.